Keros Therapeutics, Inc. — Q3 2023 Form 10-Q
Business context and reporting period. Clinical-stage biopharmaceutical company developing therapies targeting TGF-β signaling. This unaudited report covers the three and nine months ended September 30, 2023. Keros has no approved products and has not generated product-sale revenue.
Key financial metrics
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $0.008 million | $0 | $0.008 million | $0 |
| Research and development expense | $34.1 million | $21.0 million | $97.8 million | $62.4 million |
| General and administrative expense | $9.1 million | $6.9 million | $25.7 million | $20.4 million |
| Operating loss | $43.3 million | $28.0 million | $123.5 million | $82.8 million |
| Net loss | $39.4 million | $23.5 million | $112.7 million | $75.0 million |
| Net loss per share | $1.33 | $0.92 | $3.86 | $3.05 |
| Operating cash used | Not presented by quarter | Not presented by quarter | $99.0 million | $48.6 million |
At September 30, 2023, cash and cash equivalents were $287.9 million (restricted cash was an additional $1.2 million); total assets were $326.2 million and stockholders’ equity was $295.8 million. Current assets of $304.4 million compared with current liabilities of $16.7 million. The company reported no debt; operating lease liabilities totaled $14.3 million. For the nine-month period, investing cash use was $1.9 million and financing provided $109.7 million, primarily from $107.3 million net ATM proceeds. Cash, cash equivalents and restricted cash increased $8.7 million.
Material changes versus comparable periods
- Q3 net loss widened to $39.4 million from $23.5 million; nine-month net loss widened to $112.7 million from $75.0 million. The principal driver was higher R&D spending as clinical, manufacturing and personnel costs increased.
- Nine-month operating cash use more than doubled year over year, partly reflecting increased operating costs and a $9.8 million increase in prepaid expenses and other assets. The prior-year period included an $18.0 million accounts-receivable collection.
- Other income was $10.7 million for the first nine months, versus $7.9 million a year earlier. Higher money-market dividend income offset the absence of Australian R&D incentive income recognized in 2022.
- The company raised $107.3 million net through its ATM program during the first nine months, issuing approximately 2.0 million shares. Up to $141.0 million remained available under the program at quarter-end.
Outlook, commentary and risks
- Management stated in its liquidity discussion that existing cash was expected to fund operations for at least 12 months. Elsewhere in the risk factors, the company estimated cash would fund operating and capital requirements into Q4 2025; these stated runway estimates differ.
- KER-050 is in Phase 2 trials for MDS and myelofibrosis-associated cytopenias. The filing expected completion of enrollment in transfusion-dependent MDS cohorts in the first half of 2024 and described additional data and dose-escalation updates as expected in the second half of 2023.
- KER-012 is being studied in a Phase 2 PAH trial; the company also expected to start a Phase 2 heart-failure biomarker trial in the second half of 2023. KER-065 was planned to enter a Phase 1 healthy-volunteer trial in the first quarter of 2024.
- Keros deprioritized KER-047 and planned early termination of its Phase 2 MDS/myelofibrosis functional-iron-deficiency trial. The filing stated this decision was not based on safety concerns; the company was evaluating potential partnerships or other transactions.
- Management expects operating losses and negative operating cash flows to continue and R&D expenses to rise as programs advance. Additional capital will be needed beyond existing resources; future financing may dilute shareholders or may not be available on acceptable terms.
- Key risks include uncertain clinical outcomes and enrollment, reliance on third-party CROs and single-source manufacturers, competition, regulatory and reimbursement hurdles, intellectual-property risks, and exposure to inflation, supply constraints, geopolitical events and market volatility.
Most important facts for investors to verify
- Reconcile the conflicting cash-runway statements and assess burn-rate assumptions against the reported $99.0 million nine-month operating cash use.
- Check whether the clinical updates described as expected in the second half of 2023 were subsequently reported, and track enrollment and trial timelines for KER-050, KER-012 and KER-065.
- Monitor ATM share issuance, remaining offering capacity and dilution; shares outstanding rose to 29.68 million from 27.54 million at December 31, 2022.
- Assess the operational and financial implications of pausing KER-047 and the status of any potential partnership or transaction.
- Track manufacturing supply and clinical-trial execution risks, particularly the company’s reliance on single-source manufacturers for KER-050, KER-012 and KER-065.